Management of allergic and nonallergic rhinitis.
Long
A
A
McFadden
C
C
DeVine
D
D
Chew
P
P
Kupelnick
B
B
Lau
J
J
D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001249:Asthma / Q000150:complications; D018680:Cholinergic Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D004205:Cromolyn Sodium / Q000009:adverse effects / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D017410:Practice Guidelines as Topic; D012220:Rhinitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D012852:Sinusitis / Q000150:complications; D013566:Sympathomimetics / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D018680:Cholinergic Antagonists; D005938:Glucocorticoids; D006634:Histamine H1 Antagonists; D013566:Sympathomimetics; D004205:Cromolyn Sodium